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A 75 Year-Old Female
…with	a	three	year	history	of	UC	was	admitted	
with	increased	stool	frequency	and	bloody	
bowel	movements	shortly	after	completing	
a	steroid	taper.		She	had	been	initiated	on	
infliximab	at	the	time	of	her	diagnosis	but	this	
had	been	discontinued	due	to	intolerance	and	
was	being	treated	with	mesalamine	at	time	
of	admission.		Colonoscopy	revealed	severe	
pancolitis	with	mucosal	edema,	friability,	
and	spontaneous	oozing	(Image	2).		She	
was	evaluated	by	colorectal	surgery,	but	her	
preference	was	to	avoid	surgery	and	the	
decision	was	made	to	initiate	vedolizumab.		At	
this	point	her	Mayo	Clinic	score	was	≥9.		She	
received	her	first	dose	as	an	inpatient	and	
stabilized	enough	to	allow	discharge.		However,	
she	was	soon	readmitted	with	worsening	
symptoms	and	required	total	colectomy	with	
end	ileostomy.
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Image 1. Colonoscopy	revealing	continuous,	
diffuse	inflammation	consistent	with	severe	
ulcerative	colitis.
Image 3. Colon	biopsy	demonstrating	crypt	
destruction	and	loss	with	expansion	of	the	
lamina	propria	by	inflammatory	cells	and	
surface	ulceration.
Image 2. Colonoscopy	exhibiting	severe	
mucosal	changes	of	ulcerative	colitis	including	
friability,	mucus,	and	circumferential	edema	with	
oozing.
Image 4. Colon	biopsy	demonstrating	crypt	
destruction	with	expansion	of	the	lamina	propria	
by	inflammatory	cells	and	surface	ulceration.
